Volitionrx Limited · AMEX:VNRX
Volitionrx — Investor Presentation (January 2026)
25 slides from Volitionrx's investor presentation, January 2026
Slide 1: Corporate Deck January 2026
NYSE:VNRX Corporate Deck January 2026 Property of Volition© 2026 Slide 1
Slide 2: Forward Looking Statements and Disclaimer
Forward Looking Statements and Disclaimer Statements in this document may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncer
Slide 3: Executive Summary
Executive Summary Our mission is to save lives and improve outcomes for millions of people and animals worldwide. VolitionRx NYSE: VNRX Medical Devices IP Powerhouse Focus Licensing IP Cancer, Sepsis Low-cost testing Commercial Worldwide Animal $23M in licensing 1st $1M of Rev Large Unmet Needs Canc
Slide 4: Working at the Cutting Edge of Epigenetics
Working at the Cutting Edge of Epigenetics Measuring chromatin fragments Cancer NETs Global Experts in Quantifying Nucleosomes Data on file Property of Volition© 2026 Slide 4
Slide 5: Low-cost routine tests
Low-cost routine tests Platform agnostic; can be adapted to any diagnostic workflow Six 45 <10 6Hours hours 45 minutes <15 minute <10 minutes minutes <15 minutes minutes s Manual Automated Point of Care Lateral Flow Asset light - no need for own machines, labs or sales reps Property of Volition© 202
Slide 6: Commercialization
Commercialization Property Strictly Confidential of Volition©| 2026 Not for Distribution | For Discussion Purposes Only Slide 6
Slide 7: Commercialization Strategy
Commercialization Strategy Underlying principles: low capex, low opex business model focused on commercial partnerships and out- licensing R&D • R&D conducted by Volition and its research partners • Monetize IP through licensing agreements with: • upfront payments, • milestone payments, • recurring
Slide 8: Commercial Validation
Commercial Validation Case Studies: Antech and Fujifilm • Exclusive Element i+ in-house analyzer First ever Nu.Q® Vet Cancer Test Automation! licensing partnership Immunodiagnostic Systems (IDS) i10® • $10M upfront and $13M Milestone Payments automated analyzer platform received to date. Final valid
Slide 9: Recent Deals Signed
Recent Deals Signed • Research License and Exclusive Commercial Option Rights Agreement for Antiphospholipid Syndrome ("APS") for Nu.Q® NETs • Co-Marketing and Services Agreement for Nu.Q® Discover • First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical
Slide 10: Products
Products Property Strictly Confidential of Volition©| 2026 Not for Distribution | For Discussion Purposes Only Slide 10
Slide 11: Powered by Nu.Q
Powered by Nu.Q® 71 patents granted with coverage up to 2044 TAM Regulation Product Status Strategy Screening/ Clinical Sales & $4Bn Lab Developed Management Validation Licensing Multi-Cancer Proof of Sales & $23Bn CE Mark/ FDA Early Detection Concept Licensing >$3Bn First sales Sales & CE Mark/ FDA
Slide 12: Nu.Q Vet
Nu.Q® Vet Now Available in the United States, Europe, and Asia • Accurate (detects 76% of systemic cancers at 97% specificity) • Low cost, as little as $35 to veterinarian (we get $5-$13/test) • Sold 120,000+ Nu.Q® Vet Cancer Tests & Components in 2024 Recommended for older dogs and those breeds at
Slide 13: Vet Licensing & Supply Agreements to-date
Vet Licensing & Supply Agreements to-date Now Available in the United States, Europe, and Asia • IDEXX in the U.S Jan ‘23 • UK & IRE Nov ‘23 • U.S. / Aus /HK/Singapore/ some EU countries April ‘24 • July ‘24 • Portugal Nov ‘22 • Poland July ‘24 • Taiwan Nov ‘23 • Singapore Nov ‘23 Property of Voliti
Slide 14: Cancer: Nu.Q addresses all five applications of a blood test in lung cancer
Cancer: Nu.Q® addresses all five applications of a blood test in lung cancer • Expected direct sales for routine clinical use starting in France in 1H 2026. • In discussions to license out Nu.Q® Cancer with large liquid biopsy companies. Property of Volition© 2026 Slide 14
Slide 15: Neutrophil Extracellular Traps (NETs)
Neutrophil Extracellular Traps (NETs) Your angel and your devil • produced by ejecting chromosomal material out of the cell • catch and kill bacteria and viruses • can sterilize blood in minutes • first reported in 20041now the subject of > 5000 publications 1. Brinkmann V, Reichard U, Goosmann C, F
Slide 16: Sepsis Unmet Needs
Sepsis Unmet Needs The risk of death from sepsis increases by 7.6% for each hour of delay in appropriate antibiotic therapy1 Current diagnosis is empirical, multi-factorial and subjective. CURRENT methods of assessment are complex & slow. x Accepted need for improved diagnostics2 1 in 5 deaths world
Slide 17: NETs: Casting a new light on sepsis management
NETs: Casting a new light on sepsis management Satellite Symposium at ESICM LIVES 2024 Prof. Djillali Annane Professor of Medicine, University Paris Saclay-UVSQ, France “As a Critical Care Consultant, I see the devastating effects of this disease each day. I believe Nu.Q® NETs, as a diagnostic tool,
Slide 18: NETs much broader than sepsis alone
NETs much broader than sepsis alone CE Marked Nu.Q® NETs test being validated on 20+ potential clinical utilities, expected to drive clinical sales in ‘26 Clinical Applications Under Evaluation by Centers of Excellence in Europe with Nu.Q® NETs Involvement in multiple disease conditions: NETs CE-mar
Slide 19: Summary
Summary Property of Volition© 2026 Slide 19
Slide 20: Projected Catalysts
Projected Catalysts Multiple licensing deals in 2025 and 2026 Catalyst 2025 2026 2027 Licensing cancer technology Adoption into national screening program(s) Adoption into routine clinical practice Licensing Multi-Cancer Early Detection Licensing for Human NETosis / Sepsis Sales growth of CE marked
Slide 21: Volition Highlights
Volition Highlights Multiple products already launched Proven Licensing model, validated in Vet Strong IP Multiple multi-billion TAM markets Low cost, scalable platform with high margins Asset light - no need for own machines, labs, or sales reps In confidential licensing discussions with around 10
Slide 22: Lung cancer – number of tests forecasted
Lung cancer – number of tests forecasted Nu.Q® for screening and disease management to reach >3M tests by 2035* 3,500,000 3,000,000 Number of Tests 2,500,000 2,000,000 1,500,000 1,000,000 500,000 0 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 Year Screening MRD Prognostic Total *Conservative es
Slide 23: Thank You!
Thank You! Property Strictly Confidential of Volition©| 2026 Not for Distribution | For Discussion Purposes Only Slide 23
Slide 24: Cancer Studies at Centers of Excellence
Cancer Studies at Centers of Excellence Study Country Cohort Size Key Results Status NucleoCircan France 628 subjects • identify additional 23% of patients that have MRD over ctDNA alone Published • Supports clinical decision to continue first line trea or change treatment NTU Lung Taiwan 806 patien
Slide 25: NETs Studies at Centers of Excellence
NETs Studies at Centers of Excellence Study Country Description Cohort Size Status Amsterdam Netherlands Retrospective analysis of prospectively 1,713 intensive care Published. UMC collected cohort patients Multiple timepoints SISPCT Germany Retrospective analysis of prospectively 971 intensive care